Comments
Monitor says Celgene cancer drug meets late-stage goals
24.10.2012. | (Reuters) - An independent safety panel determined that Celgene Corp's experimental cancer drug had met the main goal of a late-stage trial by improving progression-free survival in multiple myeloma patients who have relapsed or not responded to prior treatment, the drugmaker said....
